Semaglutide

Drug Profile

Semaglutide

Alternative Names: NN-9535; NN-9536; NNC-0113-0217

Latest Information Update: 04 Jul 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Novo Nordisk; Zosano Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 23 Jun 2017 Novo Nordisk plans a phase III trial for obesity in 2018
  • 23 Jun 2017 Updated efficacy and adverse events data from a phase II trial in obesity released by Novo Nordisk
  • 19 May 2017 Novo Nordisk completes a phase III trial in Type-2 diabetes mellitus (Adjunctive treatment) in USA, Finland, Ireland, Germany, Latvia, Lithuania, Greece, Spain, Bulgaria, Croatia, Hong Kong, India, Portugal, Puerto Rico, Romania, Slovakia and United Kingdom (NCT02648204)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top